Trafalgar International (GCAN) EPS (Basic) Growth (1y) (2018 - 2026)
Trafalgar International (GCAN) EPS (Basic) Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -301.82% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.21% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.09% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 13.91% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 31.67% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 388.06% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30,964.57% |
| Dec 31, 2025 | 760,059.66% |
| Sep 30, 2025 | -69,790.33% |
| Jun 30, 2025 | -444.12% |
| Mar 31, 2025 | -86.73% |
| Dec 31, 2024 | 13.19% |
| Sep 30, 2024 | 17.67% |
| Jun 30, 2024 | 9.20% |
| Mar 31, 2024 | -3.58% |
| Dec 31, 2023 | 23.05% |
| Sep 30, 2023 | 58.10% |
| Jun 30, 2023 | 49.07% |
| Mar 31, 2023 | 79.75% |
| Dec 31, 2022 | 79.89% |
| Sep 30, 2022 | 67.50% |
| Jun 30, 2022 | -48.28% |
| Mar 31, 2022 | -20.99% |
| Dec 31, 2021 | 84.77% |
| Sep 30, 2021 | 85.47% |
| Jun 30, 2021 | -100.56% |